Comprehensive Stock Comparison
Compare Corcept Therapeutics Incorporated (CORT) vs Apple Inc. (AAPL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CORT | 12.8% revenue growth vs AAPL's 6.4% |
| Value | AAPL | Lower P/E (31.1x vs 97.6x) |
| Quality / Margins | AAPL | 27.0% net margin vs CORT's 13.0% |
| Stability / Safety | CORT | Beta 1.12 vs AAPL's 1.28, lower leverage |
| Dividends | AAPL | 0.4% yield; 14-year raise streak; CORT pays no meaningful dividend |
| Momentum (1Y) | AAPL | +9.7% vs CORT's -41.1% |
| Efficiency (ROA) | AAPL | 31.1% ROA vs CORT's 11.8%, ROIC 64.5% vs 6.2% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Corcept Therapeutics is a pharmaceutical company focused on developing and commercializing drugs for severe metabolic, oncologic, and neuropsychiatric disorders caused by cortisol excess. It generates revenue primarily from sales of its flagship drug Korlym for Cushing's syndrome, with future growth expected from its pipeline of selective cortisol modulators targeting additional indications. The company's competitive advantage lies in its deep expertise in cortisol modulation and intellectual property around novel glucocorticoid receptor antagonists.
Apple is a technology giant that designs and sells premium consumer electronics — most famously the iPhone — along with related software and services. It generates revenue primarily from hardware sales (roughly 80% of total) and a fast-growing services segment (around 20%) that includes the App Store, subscriptions, and licensing. Its key competitive advantage is a powerful ecosystem that locks users into its hardware, software, and services through seamless integration and high switching costs.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AAPL leads in 3 of 6 categories — strongest in Financial Metrics and Profitability & Efficiency. 2 categories are tied.
Financial Metrics (TTM)
AAPL is the larger business by revenue, generating $435.6B annually — 572.1x CORT's $761M. AAPL is the more profitable business, keeping 27.0% of every revenue dollar as net income compared to CORT's 13.0%. On growth, AAPL holds the edge at +15.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CORTCorcept Therapeut… | AAPLApple Inc. |
|---|---|---|
| RevenueTrailing 12 months | $761M | $435.6B |
| EBITDAEarnings before interest/tax | $47M | $152.9B |
| Net IncomeAfter-tax profit | $99M | $117.8B |
| Free Cash FlowCash after capex | $142M | $123.3B |
| Gross MarginGross profit ÷ Revenue | +98.3% | +47.3% |
| Operating MarginEBIT ÷ Revenue | +5.9% | +32.4% |
| Net MarginNet income ÷ Revenue | +13.0% | +27.0% |
| FCF MarginFCF ÷ Revenue | +18.6% | +28.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.1% | +15.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -23.1% | +18.3% |
Valuation Metrics
At 35.4x trailing earnings, AAPL trades at a 19% valuation discount to CORT's 43.5x P/E. On an enterprise value basis, AAPL's 27.5x EV/EBITDA is more attractive than CORT's 78.6x.
| Metric | CORTCorcept Therapeut… | AAPLApple Inc. |
|---|---|---|
| Market CapShares × price | $3.8B | $3.88T |
| Enterprise ValueMkt cap + debt − cash | $3.7B | $3.97T |
| Trailing P/EPrice ÷ TTM EPS | 43.54x | 35.41x |
| Forward P/EPrice ÷ next-FY EPS est. | 97.65x | 31.15x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.98x |
| EV / EBITDAEnterprise value multiple | 78.58x | 27.45x |
| Price / SalesMarket cap ÷ Revenue | 4.97x | 9.33x |
| Price / BookPrice ÷ Book value/share | 6.61x | 53.76x |
| Price / FCFMarket cap ÷ FCF | 26.68x | 39.33x |
Profitability & Efficiency
AAPL delivers a 133.5% return on equity — every $100 of shareholder capital generates $134 in annual profit, vs $15 for CORT. CORT carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to AAPL's 1.67x. On the Piotroski fundamental quality scale (0–9), AAPL scores 7/9 vs CORT's 5/9, reflecting strong financial health.
| Metric | CORTCorcept Therapeut… | AAPLApple Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +15.3% | +133.5% |
| ROA (TTM)Return on assets | +11.8% | +31.1% |
| ROICReturn on invested capital | +6.2% | +64.5% |
| ROCEReturn on capital employed | +6.5% | +69.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.01x | 1.67x |
| Net DebtTotal debt minus cash | -$114M | $89.7B |
| Cash & Equiv.Liquid assets | $120M | $33.5B |
| Total DebtShort + long-term debt | $6M | $123.3B |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in AAPL five years ago would be worth $21,049 today (with dividends reinvested), compared to $14,022 for CORT. Over the past 12 months, AAPL leads with a +9.7% total return vs CORT's -41.1%. The 3-year compound annual growth rate (CAGR) favors AAPL at 21.9% vs CORT's 19.7% — a key indicator of consistent wealth creation.
| Metric | CORTCorcept Therapeut… | AAPLApple Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -6.5% | -2.4% |
| 1-Year ReturnPast 12 months | -41.1% | +9.7% |
| 3-Year ReturnCumulative with dividends | +71.4% | +81.2% |
| 5-Year ReturnCumulative with dividends | +40.2% | +110.5% |
| 10-Year ReturnCumulative with dividends | +834.6% | +1027.4% |
| CAGR (3Y)Annualised 3-year return | +19.7% | +21.9% |
Risk & Volatility
CORT is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than AAPL's 1.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AAPL currently trades 91.5% from its 52-week high vs CORT's 30.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CORTCorcept Therapeut… | AAPLApple Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 1.28x |
| 52-Week HighHighest price in past year | $117.33 | $288.61 |
| 52-Week LowLowest price in past year | $28.66 | $169.21 |
| % of 52W HighCurrent price vs 52-week peak | +30.4% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 36.5 | 57.5 |
| Avg Volume (50D)Average daily shares traded | 2.3M | 40.9M |
Analyst Outlook
Wall Street rates CORT as "Buy" and AAPL as "Buy". Consensus price targets imply 91.6% upside for CORT (target: $68) vs 14.7% for AAPL (target: $303). AAPL is the only dividend payer here at 0.39% yield — a key consideration for income-focused portfolios.
| Metric | CORTCorcept Therapeut… | AAPLApple Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $68.40 | $303.11 |
| # AnalystsCovering analysts | 24 | 109 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 14 |
| Dividend / ShareAnnual DPS | — | $1.03 |
| Buyback YieldShare repurchases ÷ mkt cap | +6.5% | +2.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 100 | 307.94 | +207.9% |
| Apple Inc. (AAPL) | 100 | 361.46 | +261.5% |
Apple Inc. (AAPL) returned +110% over 5 years vs Corcept Therapeutic… (CORT)'s +40%. A $10,000 investment in AAPL 5 years ago would be worth $21,049 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | $81M | $761M | +836.3% |
| Apple Inc. (AAPL) | $215.6B | $416.2B | +93.0% |
Corcept Therapeutics Incorporated's revenue grew from $81M (2016) to $761M (2025) — a 28.2% CAGR. Apple Inc.'s revenue grew from $215.6B (2016) to $416.2B (2025) — a 7.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 10.0% | 13.1% | +30.8% |
| Apple Inc. (AAPL) | 21.2% | 26.9% | +27.0% |
Corcept Therapeutics Incorporated's net margin went from 10% (2016) to 13% (2025). Apple Inc.'s net margin went from 21% (2016) to 27% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 17.4 | 42.4 | +143.7% |
| Apple Inc. (AAPL) | 18.4 | 36.4 | +97.8% |
Corcept Therapeutics Incorporated has traded in a 16x–42x P/E range over 9 years; current trailing P/E is ~44x. Apple Inc. has traded in a 13x–41x P/E range over 9 years; current trailing P/E is ~35x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 0.07 | 0.82 | +1071.4% |
| Apple Inc. (AAPL) | 2.08 | 7.46 | +258.7% |
Corcept Therapeutics Incorporated's EPS grew from $0.07 (2016) to $0.82 (2025) — a 31% CAGR. Apple Inc.'s EPS grew from $2.08 (2016) to $7.46 (2025) — a 15% CAGR.
Chart 6Free Cash Flow — 5 Years
Corcept Therapeutics Incorporated generated $142M FCF in 2025 (-15% vs 2021). Apple Inc. generated $99B FCF in 2025 (+6% vs 2021).
CORT vs AAPL: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CORT or AAPL a better buy right now?
Apple Inc. (AAPL) offers the better valuation at 35.4x trailing P/E (31.1x forward), making it the more compelling value choice. Analysts rate Corcept Therapeutics Incorporated (CORT) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CORT or AAPL?
On trailing P/E, Apple Inc. (AAPL) is the cheapest at 35.4x versus Corcept Therapeutics Incorporated at 43.5x. On forward P/E, Apple Inc. is actually cheaper at 31.1x.
03Which is the better long-term investment — CORT or AAPL?
Over the past 5 years, Apple Inc. (AAPL) delivered a total return of +110.5%, compared to +40.2% for Corcept Therapeutics Incorporated (CORT). A $10,000 investment in AAPL five years ago would be worth approximately $21K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AAPL returned +1027% versus CORT's +834.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CORT or AAPL?
By beta (market sensitivity over 5 years), Corcept Therapeutics Incorporated (CORT) is the lower-risk stock at 1.12β versus Apple Inc.'s 1.28β — meaning AAPL is approximately 14% more volatile than CORT relative to the S&P 500. On balance sheet safety, Corcept Therapeutics Incorporated (CORT) carries a lower debt/equity ratio of 1% versus 167% for Apple Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — CORT or AAPL?
Apple Inc. (AAPL) is the more profitable company, earning 26.9% net margin versus 13.1% for Corcept Therapeutics Incorporated — meaning it keeps 26.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AAPL leads at 32.0% versus 5.9% for CORT. At the gross margin level — before operating expenses — CORT leads at 98.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CORT or AAPL more undervalued right now?
On forward earnings alone, Apple Inc. (AAPL) trades at 31.1x forward P/E versus 97.6x for Corcept Therapeutics Incorporated — 66.5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CORT: 91.6% to $68.40.
07Which pays a better dividend — CORT or AAPL?
In this comparison, AAPL (0.4% yield) pays a dividend. CORT does not pay a meaningful dividend and should not be held primarily for income.
08Is CORT or AAPL better for a retirement portfolio?
For long-horizon retirement investors, Corcept Therapeutics Incorporated (CORT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.12), +834.6% 10Y return). Both have compounded well over 10 years (CORT: +834.6%, AAPL: +1027%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CORT and AAPL?
These companies operate in different sectors (CORT (Healthcare) and AAPL (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.